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FAMILY CAREGIVING PROCESSES INDIRECTLY INFLUENCE HSCT RE-
CIPIENT QOL
Eldredge, D.H.1, Nail, L.M.1, Grant, M.2, Maziarz, R.T.1 1. Oregon
Health & Science University, Portland, OR; 2. City of Hope Medical
Center, Duarte, CA.
Background/purpose: Family caregivers (FCGs) provide much
of the outpatient care for allogeneic HSCT recipients following
stem cell transplantation. Despite the importance of family care-
giving, there is little information about how caregiving inﬂuences
the quality of life (QOL) of the HSCT recipients. The purpose of
this study is to describe the inﬂuence of family caregiving process
variables (preparedness for caregiving, predictability of caregiving,
amount of and strain from caregiving) and recipient function on
both FCG and recipient QOL.
Sample: Thirty-seven FCG-recipient dyads were recruited from
two academic medical centers on the West Coast. Both dyad
members completed questionnaires at day 45 and again at day 100
after allogeneic HSCT.
Data analysis: Descriptive statistics, correlation, and simulta-
neous regression techniques were used in this repeated measures
study. Results: QOL was measured in 4 domains: physical, psy-
chological, social, and spiritual. Recipients reported the lowest
QOL scores in social domain and the most disruption in emotional
functioning at both times. Recipients’ overall QOL scores declined
during this interval (6.2 vs 5.8; paired t  2.08; P  .04). FCGs
reported that providing emotional support was the most difﬁcult
caregiving activity and also reported the lowest quality of life in the
psychological domain. FCGs overall QOL scores remained stable
during the study interval (6.0 vs 5.7; ns). At day 45, the combina-
tion of preparedness, predictability, caregiving strain, and recipient
function accounted for 39% of the variance in FCG QOL (F,725 
3.88; P  .005); however, none of these variables were unique
predictors of FCG QOL. At day 100, this set of variables did not
explain FCG QOL. The set of caregiving process variables did not
explain recipient QOL. However, the combination of disruption in
recipient function and FCG QOL accounted for 26% of the
variance in recipient QOL at day 45; both recipient function (t 
2.06, P  .05) and FCG QOL (t  2.09; P  .04) uniquely
predicted recipient QOL. Recipient QOL at day 100 was not
explained by recipient function or FCG QOL. Conclusions: At
day 45, caregiving process variables inﬂuence FCG QOL, but do
not have direct inﬂuence on recipient QOL. FCGs need ongoing
assistance to provide emotional support to HSCT recipients. One
way to improve recipient QOL may be to address FCG concerns
about recipient functional status.
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GIANT CONDYLOMATA ACUMINATA: A RARE COMPLICATION OF AL-
LOGENEIC BONE MARROW TRANSPLANTATION
Ganguly, S.1, Waller, S.1, Skikne, B.1 University of Kansas Medical
Center, Kansas City, KS.
Introduction: Human Papilloma Virus (HPV) types 16 and 18
cause instability of P53 tumor suppressor gene and have the po-
tential to cause ano-genital carcinoma. In patients with chronic
graft-versus-host disease (GVHD), ongoing use of immunosup-
pressive agents may cause rapid replication of HPV with a subse-
quent risk of malignant transformation. We identiﬁed one case of
giant condylomata acuminata among 312 allogeneic marrow trans-
plantation recipients at University of Kansas Medical Center be-
tween 1977 and 2005. Case Report: A 38-year-old male was seen
in June 2005 at post-transplant follow-up clinic with painful anal
lesions and constipation. He had a past history of chronic myeloid
leukemia for which he underwent HLA matched sibling donor
stem cell transplantation in 2003. Since then, his course had been
complicated by GVHD involving skin, mucosa, and liver. He had
been maintained on tacrolimus, mycophenolate, mofetil, and pred-
nisone for the treatment of chronic GVHD. On examination, he
was found to have giant peri-anal condylomata acuminata occlud-
ing the anal oriﬁce. He was initially treated by surgical excision and
fulguration of condylomata. Post-procedure, he was treated with
5% imiquimod cream. He remains symptom free and without
recurrence of condylomata acuminata as of today. Biopsy of the
lesion did not show any area of malignant transformation or dys-
plasia. Immunostains were positive for HPV types 6 and 11, and
negative for types 16 and 18. Discussion: Giant condylomata
acuminata after bone marrow transplantation is rare. Due to on
going chronic GVHD in our patient, his risk of recurrence will be
high. Malignant transformation of condylomata acuminata has
been reported in solid organ transplant patients. We hope that our
patient’s risk for malignant transformation would be low due to
absence of HPV types 16 and 18. However, we plan to follow our
patient closely and any recurrence would be treated aggressively.
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FAVORABLE LATE OUTCOMES FOLLOWING UNRELATED DONOR BONE
MARROW TRANSPLANTATION WHEN ANTI-THYMOCYTE GLOBULIN IS
USED AS A PART OF CONDITIONING
Adess, M.E.1, Toor, A.A.1, Stiff, P.J.1, Rodriguez, T.E.1, Norton, J.1,
Parthasarthy, M.1, Fox-Geiman, M.1, Smith, S.E.1, Klein, J.L.1 Bone
Marrow Transplant, Dept of Medicine, Loyola University Medical Cen-
ter, Maywood, IL.
Polyclonal anti-thymocyte globulin (ATG) ameliorates the risk
for primary graft rejection as well as acute graft-versus-host disease
(GVHD) by depleting T cells in both the host and the allograft.
However, the impact of ATG on late outcomes is less clear. We
report the results of a landmark analysis of patients who survived
beyond 90 days following unrelated donor bone marrow transplan-
tation (n  35) comparing outcomes in patients conditioned with
(n  17) or without ATG (n  18). Conditioning was with either
Busulfan/Cytoxan (n  24) or BCNU/Etoposide/Ara-C/Melpha-
lan (n  11). Most of the ATG patients (12) recieved rabbit ATG,
at a median dose of 3 mg/kg (range 2.5–9 mg/kg). The others were
given equine ATG 60 mg/kg. ATG was given on day 4 and 3.
GVHD prophylaxis consisted of tacrolimus  methotrexate in
both groups. Median age was 43 years (range 18–65; 12 female).
Diseases treated were CML (8), MDS/CMPD (7), AML (7), HD
(6), MM (3), NHL (2), and CLL (2). A median of 3 prior therapies
had been given before transplant (range 1–5) and 14 patients (39%)
had failed a prior autograft. Most patients were beyond CR1 or
CP1 (n 27). With a median follow up of 22 months (range 12–49
mo), the median survival in the no ATG cohort was 12 months and
has not been reached in the ATG cohort. The 1-year and 2-year
survival in the ATG versus no ATG cohorts are 82% versus 50%
and 60% versus 50%, respectively (P  NS by Log-Rank test).
Chronic GVHD developed in 13/18 patients not receiving ATG (7
extensive) and 8/17 (3 extensive) in ATG containing regimens (P
NS). One patient in each arm of the study rejected their graft.
Relapse rate was the same in the ATG group compared to the
non-ATG group (4/17 vs 2/18; P  NS). Lymphoid recovery was
similar in the two groups as well, absolute lymphocyte counts at
day 90 and day 180 post transplant were 500 versuss 600/mL and
700 versus 950/mL in the no ATG vs ATG cohorts. Serious
infections requiring parenteral antibiotic treatment occurred in 5
patients receiving ATG, and 9 patients in the non-ATG arm. Nine
patients have died in the no ATG cohort from relapse (2), GVHD
(2), or infection (5); whereas in the ATG cohort 6 have died of
relapse (2), GVHD (3) or infection (1). In conclusion, there is a
trend towards fewer delayed transplant related complications in
patients receiving bone marrow from unrelated donors when ATG
is used as a part of conditioning.
LYMPHOMA/MULTIPLE MYELOMA
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EQUIVALENT DISEASE FREE AND OVERALL SURVIVAL IN LYMPHOMA
PATIENTS TREATED WITH EITHER MYELOABLATIVE (MA) OR NON-
MYELOABLATIVE (NMA) CONDITIONING AND ALLOGENEIC STEM CELL
TRANSPLANT (SCT)
Tomblyn, M.R.1, Brunstein, C.1, Burns, L.J.1, Miller, J.S.1, Tan, Y.1,
Weisdorf, D.1 University of Minnesota Division of Hematology, Oncol-
ogy, and Transplantation, Minneapolis, MN.
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